• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    11/6/24 3:13:14 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    SC 13G 1 Monopar103124.txt JANUS OWNS OVER 10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: MONOPAR THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 61023L207 Date of Event Which Requires Filing of this Statement: 10/31/2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No.: 61023L207 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Group plc EIN #00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Jersey, Channel Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 562,482** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 562,482** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 562,482** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.9%** 12. TYPE OF REPORTING PERSON IA, HC ** See Item 4 of this filing CUSIP No.: 61023L207 1. NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Janus Henderson Biotech Innovation Master Fund Ltd 00-0000000 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP a. ___ b. ___ 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0** 6. SHARED VOTING POWER 504,585** 7. SOLE DISPOSITIVE POWER 0** 8. SHARED DISPOSITIVE POWER 504,585** 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 504,585** 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.8%** 12. TYPE OF REPORTING PERSON IV ** See Item 4 of this filing Item 1. (a). Name of Issuer: MONOPAR THERAPEUTICS INC ("Monopar") (b). Address of Issuer's Principal Executive Offices: 1000 SKOKIE BLVD SUITE 350 WILMETTE, IL 60091 Item 2. (a).-(c). Name, Principal Business Address, and Citizenship of Persons Filing: (1) Janus Henderson Group plc 201 Bishopsgate EC2M 3AE, United Kingdom Citizenship: Jersey, Channel Islands (2) Janus Henderson Biotech Innovation Master Fund Ltd 151 Detroit Street Denver, Colorado 80206 Citizenship: Massachusetts (d). Title of Class of Securities: Common Stock (e). CUSIP Number: 61023L207 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the person filing, Janus Henderson Group plc ("Janus Henderson") is a parent holding company/control person in accordance with Section 240.13d-1(b)(ii)(G). See Item 4 for additional information. Janus Henderson Biotech Innovation Master Fund Ltd is an Investment Company registered under Section 8 of the Investment Company Act of 1940. Item 4. Ownership The information in items 1 and 5 through 11 on the cover page(s) on Schedule 13G is hereby incorporated by reference. Janus Henderson has a 100% ownership stake in Janus Henderson Investors U.S. LLC ("JHIUS"), Janus Henderson Investors UK Limited ("JHIUKL") and Janus Henderson Investors Australia Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset Manager" and collectively as the "Asset Managers"). Due to the above ownership structure, holdings for the Asset Managers are aggregated for purposes of this filing. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as "Managed Portfolios"). As a result of its role as investment adviser or sub-adviser to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 562,482 shares or 10.9% of the shares outstanding of Monopar Common Stockheld by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. Janus Henderson Biotech Innovation Master Fund Ltd is an investment company registered under the Investment Company Act of 1940 and is one of the Managed Portfolios to which JHIUS provides investment advice. Item 5. Ownership of Five Percent or Less of a Class Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person The Managed Portfolios, set forth in Item 4 above, have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. The interest of one person, Janus Henderson Biotech Innovation Master Fund Ltd, an investment company registered under the Investment Company Act of 1940, in Monopar Common Stock amounted to 504,585 shares or 9.8% of the total outstanding Common Stock. These shares were acquired in the ordinary course of business, and not with the purpose of changing or influencing control of the Issuer. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 11/6/2024 Janus Henderson Biotech Innovation Master Fund Ltd By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Date 11/6/2024 Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his or her authorized representative. If the statement is signed on behalf of a person by his or her authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement (see Exhibit A), provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his or her signature. EXHIBIT A POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary EXHIBIT B JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of MONOPAR THERAPEUTICS INC and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned hereby execute this Agreement as of the 6th day of November, 2024. JANUS HENDERSON GROUP PLC By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO Janus Henderson Biotech Innovation Master Fund Ltd By /s/ Kristin Mariani Kristin Mariani, Head of North America Compliance, CCO
    Get the next $MNPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    10/11/2024$50.00Buy
    Rodman & Renshaw
    11/1/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNPR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

      SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)

      5/14/25 11:59:32 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Monopar Therapeutics Inc.

      10-Q - Monopar Therapeutics (0001645469) (Filer)

      5/13/25 8:00:57 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Monopar Therapeutics (0001645469) (Filer)

      5/13/25 8:00:09 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

      Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

      6/22/24 8:00:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

      SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

      12/17/24 5:01:42 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Monopar Therapeutics Inc.

      SC 13G - Monopar Therapeutics (0001645469) (Subject)

      11/6/24 3:13:14 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Monopar Therapeutics Inc.

      SC 13G - Monopar Therapeutics (0001645469) (Subject)

      10/31/24 4:17:57 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/4/25 7:27:32 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew covered exercise/tax liability with 744 shares and converted options into 1,791 shares, increasing direct ownership by 3% to 41,985 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/2/25 9:08:37 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Robinson Chandler converted options into 4,106 shares and covered exercise/tax liability with 1,204 shares, increasing direct ownership by 5% to 65,993 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      4/2/25 9:07:37 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    See more
    • Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

      Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

      1/23/25 1:10:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

      WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini

      7/12/21 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

      WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization

      6/1/21 4:05:00 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

      WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced first quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On May 7, 2025, Monopar presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline) at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, a leading global conference in liver disease. The data support ALXN1840 as a potential treatment for Wilson disease

      5/13/25 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

      WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025. The poster supports the potential use o

      5/7/25 2:30:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

      WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025. Late-breaker provides an opportunity to present "

      4/29/25 8:00:00 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Monopar Therapeutics with a new price target

      Piper Sandler resumed coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $76.00

      3/19/25 8:17:26 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Monopar Therapeutics with a new price target

      Piper Sandler initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $72.00

      1/10/25 8:29:30 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Monopar Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $50.00

      10/11/24 7:49:44 AM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      10/30/24 4:17:28 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/21/24 5:16:51 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

      4 - Monopar Therapeutics (0001645469) (Issuer)

      6/17/24 6:08:20 PM ET
      $MNPR
      Biotechnology: Pharmaceutical Preparations
      Health Care